Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Trial Profile

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs PGN 650 I-124 (Primary)
  • Indications Solid tumours
  • Focus Diagnostic use
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 03 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 03 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top